Cytokinetics Statistics
Total Valuation
Cytokinetics has a market cap or net worth of $3.91 billion. The enterprise value is $3.80 billion.
Important Dates
The last earnings date was Tuesday, May 6, 2025, after market close.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytokinetics has 119.43 million shares outstanding. The number of shares has increased by 18.23% in one year.
| Current Share Class | 119.43M |
| Shares Outstanding | 119.43M |
| Shares Change (YoY) | +18.23% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 0.46% |
| Owned by Institutions (%) | 116.06% |
| Float | 118.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 193.84 |
| Forward PS | 56.49 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 197.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.99
| Current Ratio | 5.99 |
| Quick Ratio | 5.89 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.14 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -34.12% |
| Return on Invested Capital (ROIC) | -70.51% |
| Return on Capital Employed (ROCE) | -51.22% |
| Revenue Per Employee | $38,590 |
| Profits Per Employee | -$1.24M |
| Employee Count | 498 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.12% in the last 52 weeks. The beta is 0.59, so Cytokinetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -40.12% |
| 50-Day Moving Average | 35.68 |
| 200-Day Moving Average | 46.68 |
| Relative Strength Index (RSI) | 48.03 |
| Average Volume (20 Days) | 1,669,001 |
Short Selling Information
The latest short interest is 15.60 million, so 13.06% of the outstanding shares have been sold short.
| Short Interest | 15.60M |
| Short Previous Month | 14.48M |
| Short % of Shares Out | 13.06% |
| Short % of Float | 13.13% |
| Short Ratio (days to cover) | 6.64 |
Income Statement
In the last 12 months, Cytokinetics had revenue of $19.22 million and -$615.26 million in losses. Loss per share was -$5.30.
| Revenue | 19.22M |
| Gross Profit | -338.46M |
| Operating Income | -565.64M |
| Pretax Income | -545.28M |
| Net Income | -615.26M |
| EBITDA | -556.14M |
| EBIT | -565.64M |
| Loss Per Share | -$5.30 |
Full Income StatementBalance Sheet
The company has $938.22 million in cash and $910.46 million in debt, giving a net cash position of $27.76 million or $0.23 per share.
| Cash & Cash Equivalents | 938.22M |
| Total Debt | 910.46M |
| Net Cash | 27.76M |
| Net Cash Per Share | $0.23 |
| Equity (Book Value) | -266.41M |
| Book Value Per Share | -2.23 |
| Working Capital | 796.33M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$398.00 million and capital expenditures -$9.57 million, giving a free cash flow of -$407.57 million.
| Operating Cash Flow | -398.00M |
| Capital Expenditures | -9.57M |
| Free Cash Flow | -407.57M |
| FCF Per Share | -$3.41 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -2,943.30% |
| Pretax Margin | -3,201.47% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cytokinetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.23% |
| Shareholder Yield | -18.23% |
| Earnings Yield | -16.06% |
| FCF Yield | -10.64% |
Dividend DetailsAnalyst Forecast
The average price target for Cytokinetics is $73.71, which is 125.03% higher than the current price. The consensus rating is "Buy".
| Price Target | $73.71 |
| Price Target Difference | 125.03% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 140.78% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 25, 2013. It was a reverse split with a ratio of 0.1666666:1.
| Last Split Date | Jun 25, 2013 |
| Split Type | Reverse |
| Split Ratio | 0.1666666:1 |
Scores
Cytokinetics has an Altman Z-Score of -1.46 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.46 |
| Piotroski F-Score | 3 |